| Literature DB >> 25192547 |
Marc López-Roig1, Hervé Bourhy2, Rachel Lavenir3, Jordi Serra-Cobo4.
Abstract
We report an active surveillance study of the occurrence of specific antibodies to European Bat Lyssavirus Type 1 (EBLV-1) in bat species, scarcely studied hitherto, that share the same refuge. From 2004 to 2012, 406 sera were obtained from nine bat species. Blood samples were subjected to a modified fluorescent antibody virus neutralization test to determine the antibody titer. EBLV-1-neutralizing antibodies were detected in six of the nine species analyzed (Pipistrellus pipistrellus, P. kuhlii, Hypsugo savii, Plecotus austriacus, Eptesicus serotinus and Tadarida teniotis). Among all bats sampled, female seroprevalence (20.21%, 95% CI: 14.78%-26.57%) was not significantly higher than the seroprevalence in males (15.02%, 95% CI: 10.51%-20.54%). The results showed that the inter-annual variation in the number of seropositive bats in T. teniotis and P. austriacus showed a peak in 2007 (>70% of EBLV-1 prevalence). However, significant differences were observed in the temporal patterns of the seroprevalence modeling of T. teniotis and P. austriacus. The behavioral ecology of these species involved could explain the different annual fluctuations in EBLV-1 seroprevalence.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25192547 PMCID: PMC4189026 DOI: 10.3390/v6093386
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Figure 1San Pedro de los Griegos pothole.
The serological results of European Bat Lyssavirus Type 1 (EBLV-1) neutralizing antibodies analyzed by all bat species captured in the San Pedro de los Griegos pothole (2004–2012).
| Species | Females | Males | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n | n+ | % (95 CI) | n | n+ | % (95 CI) | n | n+ | % (95 CI) | |
| nd | nd | nd | 9 | 1 | 11.11 (0.3–48.2) | 9 | 1 | 11.11 (0.3–48.2) | |
| 7 | 0 | 0 | 15 | 5 | 33.33 (11.8–61.6) | 22 | 5 | 22.73 (7.8–45.4) | |
| 1 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | |
| nd | nd | nd | 1 | 0 | 0 | 1 | 0 | 0 | |
| 76 | 13 | 17.10 (9.4–27.5) | 56 | 8 | 14.28 (6.4–26.2) | 132 | 21 | 15.91 (10.1–23.3) | |
| 6 | 1 | 16.67 (0.4–64.1) | 2 | 0 | 0 | 8 | 1 | 12.50 (0.3–52.6) | |
| 9 | 2 | 20.22 (2.8–60.0) | 19 | 2 | 10.53 (1.3 –33.1) | 28 | 4 | 14.28 (4.0–32.7) | |
| nd | nd | nd | 2 | 0 | 0 | 2 | 0 | 0 | |
| 94 | 23 | 24.47 (16.2–34.4) | 108 | 16 | 14.81 (8.7–22.9) | 202 | 39 | 19.31 (14.1–25.4) | |
| Total | 193 | 39 | 20.21 (14.8–26.6) | 213 | 32 | 15.02 (10.5–20.5) | 406 | 71 | 17.49 (13.9–21.5) |
n: number of individuals analyzed; n+: number of seropositive bats; CI: 95% confidence intervals; nd: no data.
Individual serological follow-up in captured-mark-recaptured P. austriacus.
| Sex | Id | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Females | 1 | 0 | ns | ns | ns | ns | 0 | 0 | ns | 52 |
| 2 | ns | 0 | ns | ns | 56 | ns | 43 | ns | ns | |
| 3 | ns | 0 | ns | 56 | ns | ns | ns | ns | ns | |
| 4 | ns | ns | ns | ns | 35 | ns | ns | 0 | ns | |
| 5 | ns | ns | ns | 58 | 0 | ns | ns | ns | ns | |
| 6 | ns | ns | ns | 147 | 0 | ns | ns | ns | ns | |
| Males | 7 | ns | ns | 35 | 48 | ns | ns | ns | 0 | ns |
| 8 | ns | ns | ns | nd | 53 | ns | ns | ns | ns | |
| 9 | ns | ns | nd | 49 | ns | ns | ns | ns | ns |
Id: identification number of individuals; ns: not sampled; nd: no serological data.
Figure 2Evolution of percentage of EBLV-1 seropositive bats by species from 2004 to 2012. Black circles for P. austriacus, grey circles for T. teniotis and black triangles for other species (E. serotinus, E.s; H. savii, H.s, P. kuhlii, P.k; and P. pipistrellus, P.p).
The number of bat samples analyzed during the nine-year period.
| Years | Females | Males | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n | n+ | % (95 CI) | n | n+ | % (95 CI) | n | n+ | % (95 CI) | |
| 2004 | 55 | 6 | 10.91 (4.1–22.2) | 55 | 1 | 1.82 (0.0–9.7) | 110 | 7 | 6.36 (2.6–12.7) |
| 2005 | 7 | 0 | 0 | 15 | 0 | 0 | 22 | 0 | 0 |
| 2006 | 30 | 9 | 30.00 (14.7–49.4) | 20 | 3 | 15.00 (3.2–37.9) | 50 | 12 | 24.00 (13.1–38.2) |
| 2007 | 18 | 14 | 77.78 (52.4–93.6) | 16 | 10 | 62.50 (35.4–84.8) | 34 | 24 | 70.59 (52.5–84.9) |
| 2008 | 13 | 3 | 23.08 (5.0–53.8) | 30 | 6 | 20.00 (7.7–38.6) | 43 | 9 | 20.93 (10.0–36.0) |
| 2009 | 17 | 0 | 0 | 24 | 0 | 0 | 41 | 0 | 0 |
| 2010 | 16 | 1 | 6.25 (0.1–30.2) | 14 | 2 | 14.29 (1.8–42.8) | 30 | 3 | 10.00 (2.1–26.5) |
| 2011 | 26 | 4 | 15.38 (4.4–34.9) | 23 | 8 | 34.78 (16.4–57.3) | 49 | 12 | 24.49 (13.3–38.9) |
| 2012 | 11 | 2 | 18.18 (2.3–51.8) | 16 | 2 | 12.50 (1.5–38.3) | 27 | 4 | 14.81 (4.2–33.7) |
n: number of individuals analyzed; n+: number of seropositive bats; CI: 95% confidence intervals; nd: no data.
The number of bat samples analyzed, by bat species and year.
| Years | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| n | n+ | % (95 CI) | n | n+ | % (95 CI) | n | n+ | % (95 CI) | |
| 2004 | 5 | 0 | 0 | 4 | 1 | 25.00 (0.6–80.6) | 3 | 0 | 0 |
| 2005 | nd | nd | nd | 1 | 0 | 0 | 1 | 0 | 0 |
| 2006 | 1 | 0 | 0 | nd | nd | nd | 1 | 0 | 0 |
| 2007 | nd | nd | nd | nd | nd | nd | 2 | 2 | 100.00 (22.4–100.0) |
| 2008 | nd | nd | nd | nd | nd | nd | 2 | 2 | 100.00 (22.4–100.0) |
| 2009 | nd | nd | nd | nd | nd | nd | 9 | 0 | 0 |
| 2010 | 1 | 0 | 0 | nd | nd | nd | nd | nd | nd |
| 2011 | nd | nd | nd | 3 | 0 | 0 | 4 | 1 | 25.00 (0.6–80.6) |
| 2012 | 2 | 1 | 50.00 (1.3–98.7) | nd | nd | nd | nd | nd | nd |
The number of bat samples analyzed, by bat species and year.
| Years | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| n | n+ | % (95 CI) | n | n+ | % (95 CI) | n | n+ | % (95 CI) | |
| 2004 | 7 | 0 | 0 | 34 | 0 | 0 | 57 | 6 | 10.53 (4.0–21.5) |
| 2005 | 2 | 0 | 0 | 13 | 0 | 0 | 5 | 0 | 0 |
| 2006 | 2 | 0 | 0 | 11 | 2 | 18.18 (2.3–51.8) | 35 | 10 | 28.57 (14.6–46.3) |
| 2007 | 1 | 0 | 0 | 14 | 11 | 78.57 (49.2–95.3) | 17 | 11 | 64.71 (38.3–85.8) |
| 2008 | 3 | 3 | 100.00 (36.8–100.0) | 16 | 4 | 25.00 (7.3–52.4) | 22 | 0 | 0 |
| 2009 | 7 | 0 | 0 | 5 | 0 | 0 | 16 | 0 | 0 |
| 2010 | nd | nd | nd | 12 | 1 | 8.33 (0.2–38.5) | 17 | 2 | 11.76 (1.5–36.4) |
| 2011 | 4 | 1 | 25.00 (0.6–80.6) | 16 | 1 | 6.25 (0.2–30.2) | 21 | 9 | 42.86 (21.8–66.0) |
| 2012 | 2 | 0 | 0 | 11 | 2 | 18.18 (2.3–51.8) | 12 | 1 | 8.33 (0.2–38.5) |
n: number of individuals analyzed; n+: number of seropositive bats; nd: no data; CI: 95% confidence intervals; nd: no data.
Model building results for the generalized additive models (GAM) relating EBLV-1-antibody prevalence and explanatory variables.
| GAM model expression | AICc | ΔAICc |
|---|---|---|
| 1- seroprevalence ~ s(year,by = | 273.22 | 0.00 |
| 2- seroprevalence ~ sex + s(year) | 286.49 | 13.27 |
| 3- seroprevalence ~ s(year) | 286.90 | 13.68 |
| 4- seroprevalence ~ sex + species + s(year) | 287.75 | 14.53 |
| 5- seroprevalence ~ species + s(year) | 288.39 | 15.17 |
| 6- seroprevalence ~ sex × species + s(year) | 289.53 | 16.31 |
Figure 3Spline fit (solid line) with 95% confidence interval (dashed lines) of the variability in the EBLV-1 seroprevalence as a function of years (GAM: EBLV-1-antibody prevalence ~ intercept + s(year, by = P. austriacus) + s(year, by = T. teniotis)). (Left) T. teniotis; (right) P. austriacus.